Human pancreatic growth hormone releasing factor ) is the parent molecule of several peptides recently extracted from pancreatic tumours associated with acromegaly. A study was conducted to examine its effects on the release of growth hormone in normal volunteers and in patients with hypopituitarism and acromegaly.
advantage of being free of side effects and readily performed in outpatients. Hence it seems likely to become the standard test and take the place of the insulin stress test. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Tyr-Ala -Asp-Ala -lie-Phe-Thr -Asn-Ser-Tyr -A rg -Lys -Val-Leu-Gly- Figure 1 shows the primary structure of the largest of these peptides (GRF ). This peptide and two smaller peptides, possibly degradation products and GRF (1-37)), were present in one tumour,6 8 while only the 40 amino acid form was isolated from another tumour.7 Analogues of these peptides have now been synthesised and it has been shown that the N-terminal 29 residues possess full growth hormone secretagogue activity in vitro.7 The relation of these peptides to the hypothalamic growth hormone releasing factors remains unknown. Comparison between GRF (1-40) and partially purified rat hypothalamic GRF, however, suggests a close similarity in structure and activity.7 It has for a long time been apparent that insulin induced hypoglycaemia is a poor way of assessing pituitary somatotroph function. The stimulus itself is very variable, the test unpleasant, and medical supervision is required.
The effects of bolus doses of GRF (1-40) have recently been reported in man, where it is found specifically to stimulate growth hormone secretion with no effect on other anterior pituitary function.9 Nevertheless, no studies on the effects of the complete molecule GRF (1-44) on growth hormone secretion in man have been reported, nor has the influence of such peptides on secretion in growth hormone deficient or excess states, We have therefore examined these effects and report our findings.
Subjects and methods
Normal subjects-We studied 11 male volunteers (mean age 24 years). All were within 15% of ideal body weight and were in good Figure 2 illustrates the intersubject variability in the normal response of growth hormone to 100 jig GRF (1-44). In all 11 subjects the onset of the response was rapid, in that there was a measurable rise in concentration within five minutes of the bolus injection of GRF (1-44). The peak value was reached between 12 and 50 minutes, occurring in nine subjects by 30 minutes, and varied between 13 and 67 mU/l, with a mean peak value of 31 8±41 mU/l at 30 minutes. Values had fallen to 11 mU/1 or below by 120 minutes. Figure 3 shows the mean growth hormone responses to 10, 30, and 100 pig GRF (1-44). (1 mU/l). Two had no response to GRF (1-44) (table III, cases 4 and 7); the remainder had very much smaller responses compared with normal subjects, with peak growth hormone values between 12 and 7 3 mU/l occurring from 40 to 60 minutes after GRF (1-44), and in four of these patients the values had not returned to < 1 mU/I at 120 minutes (table III, Table III compares the growth hormone responses to GRF (1-44) and hypoglycaemia in each patient. In those who responded to both stimuli the response to GRF (1-44) was of more rapid onset and tended to be greater. Two patients (cases 1 and 5) showed no response to hypoglycaemia but had measurable rises of growth hormone after GRF, possibly indicating hypothalamic in addition to pituitary dysfunction in these patients. There was good correlation between the two tests in those patients who primarily had pituitary disease. None of the normal volunteers or patients with acromegaly or growth hormone deficiency showed any appreciable change in pulse or blood pressure. Similarly there was no change in blood glucose concentration (measured in all samples) in any subject, including the two diabetic patients. The only subjective effect reported was in one normal volunteer who noted transient warmth of his face immediately after the 100 ,ug dose, which was more pronounced after 200 ,ug; and in the same subject flushing of the face occurred at the higher dose but not the lower and was of short duration.
Discussion
GRF (1-44) is one of a group of peptides recently isolated from a pancreatic tumour6 which potently and specifically stimulates growth hormone secretion in vitro3 613 and in vivo in animals. '4 15 There is considerable evidence that this ectopic peptide resembles hypothalamic GRF in structure and function.7
A previous study has shown GRF (1-40) specifically to release growth hormone in man.9 The effects of the entire molecule (GRF (1-44)) on growth hormone release in man have not previously been investigated and are reported here both in health and disease. Interestingly comparison of the growth hormone rises suggests that they are roughly equipotent.
GRF (1-44) was found dose dependently to stimulate release of growth hormone in normal man. The response was rapid with the mean peak response occurring at 30 minutes, and the mean growth hormone concentration had returned almost to basal values by 120 minutes. Pulse rate and blood pressure were unaffected, and the only mild side effect was warmth of the face in one subject associated with facial flushing at the highest dose. There was considerable intersubject variation in the magnitude of response, which may reflect variability either in the pituitary's responsiveness to GRF or in the counterregulatory effects of the inhibitory peptide somatostatin, as has been reported in animals. 15 The control subjects were considerably younger than the patients with acromegaly or hypopituitarism; however, the growth hormone concentration does not vary with age and therefore we think that it is valid to compare the responses.
The growth hormone response to GRF (1-44) in acromegaly is of considerable interest. Although the numbers were small, the patients with pituitary adenomas secreting growth hormone fell within two groups as regards their response to GRF (1-44). One group of patients had an absolute rise in growth hormone values within the same range as normal subjects, and these patients had shown at least a 20% suppression of growth hormone in response to glucose. In contrast, the other group had a very large rise in growth hormone values in response to GRF (1-44), and these either showed only a small suppression or showed a paradoxical rise of growth hormone to glucose. An exaggerated response to GRF (1-44) therefore seems to suggest more active disease.
GRF (1-44) was found to be at least as potent in releasing growth hormone as insulin hypoglycaemia in patients with known hypopituitarism. The growth hormone responses to GRF (1-44) and to insulin induced hypoglycaemia were indeed comparable in our eight patients, but the response to GRF was of more rapid onset, providing the basis for a shorter stimulation test. Possibly the response to GRF (1-44) allows a distinction between a hypothalamic and pituitary defect in that in the hypothetical former case the growth hormone response may be normal. Growth hormone cell hypoplasia, secondary to failure of GRF drive, might, however, confuse the response. Avoiding the dangers of hypoglycaemia together with the total lack of side effects of GRF appear to favour strongly the use of this peptide instead of insulin as a routine growth hormone stimulation test. In addition, the time of the peak growth hormone response to GRF would fit well with the responses to the other releasing hormones thyrotrophin releasing hormone and luteinising hormone releasing hormone. One would anticipate that the further addition of corticotrophin releasing factor would allow the insulin tolerance test to be totally superseded.
Our studies on the effects of GRF (1-44) on secretion of growth hormone in normal man and patients with hypopituitarism and acromegaly suggest that it will prove to be of considerable use in assessing growth hormone releasing hormone and luteinising hormone releasing hormone test in 14 women with the disorder.
Subjects and methods
Women complaining of generalised swelling and with a documented diurnal weight gain in excess of 14 kg were considered to have cyclical oedema provided that other causes of oedema had been excluded by physical examination and biochemical investigation. We studied 14 patients (mean age 35±SEM 30 years and mean weight 67 ±3-5 kg) and six normal female volunteers (mean age 32±2-5 years and mean weight 61 5±2-0 kg). No subject in either group was taking an oral contraceptive pill, but most patients had previously received diuretics. Whenever possible diuretic treatment was slowly withdrawn so that at the time of the study eight patients had stopped taking diuretics a minimum of three months previously, three were receiving them, and three had never received them. Informed consent was obtained, and the study was approved by the hospital research ethics committee.
All subjects were studied during the preovulatory phase of the menstrual cycle as confirmed by plasma oestradiol and progesterone concentrations. The study was conducted by the same investigator with the subjects recumbent after an overnight stay in hospital. A light standard breakfast was given at 0800 and an intravenous cannula inserted at 0900. At 1000 basal blood samples were taken for measurement of concentrations of oestradiol, progesterone, prolactin, testosterone, leuteinising hormone, follicle stimulating hormone, and thyroid stimulating hormone. Consecutive injections of 100 jig luteinising hormone releasing hormone (Gonadorelin, Ayerst) and 200 jig thyrotrophin releasing hormone (Roche) were then given and blood samples taken at 20, 40, 60, 90, 120, and 150 
